Brain tumors are shrunk through surgery, radiation, chemotherapy, targeted drugs, or a combination of these, depending on the tumor’s type, size, and location. No single approach works for every tumor, and the strategy your medical team recommends will look very different for a slow-growing benign meningioma than for an aggressive glioblastoma. Here’s what each treatment actually does and what kind of results it can produce.
Surgery: The Most Direct Option
When a brain tumor is accessible, surgical removal is the fastest way to reduce its size. The goal in most cases is what surgeons call gross total resection, meaning they remove all visible tumor tissue. With modern image-guided techniques (fluorescent dyes that make tumor cells glow, real-time MRI, and intraoperative ultrasound), surgeons achieve complete removal in roughly 79% of glioblastoma cases. Without those tools, using standard visualization alone, that rate drops to about 52%.
Not all tumors can be fully removed. If a tumor sits near areas controlling speech, movement, or vision, surgeons may intentionally leave a portion behind to protect brain function. Even partial removal reduces the tumor’s bulk, relieves pressure, and makes follow-up treatments like radiation more effective. Meningiomas, the most common benign brain tumors, can often be cured with excision alone because they grow on the brain’s outer membranes rather than infiltrating deep tissue.
Radiation Therapy and Radiosurgery
Radiation shrinks tumors by damaging the DNA inside tumor cells so they can no longer divide. Over time, those cells die off, the tumor loses its blood supply as surrounding vessels close, and the mass gradually gets smaller. There are two broad categories: conventional radiation therapy, delivered in small daily doses over several weeks, and stereotactic radiosurgery, which delivers a high, precisely focused dose in one to five sessions.
How quickly you see results depends on the tumor type. Cancerous tumors tend to shrink within a few months of treatment. Benign tumors respond more slowly, typically shrinking over 18 months to two years, though the primary goal with benign tumors is often to stop future growth rather than eliminate the mass entirely. For low-grade gliomas, the shrinkage window is even wider. These tumors gradually decrease in size over a period that ranges from about 6 months to 4 years after a standard six-week course of radiation.
Your doctor will typically schedule a follow-up MRI about three months after radiation to check for early responders. Some patients see noticeable reduction at that point, while others won’t show meaningful change for a year or more. This doesn’t necessarily mean the treatment failed. The timeline varies significantly from person to person.
Chemotherapy for Malignant Tumors
Chemotherapy drugs travel through the bloodstream to reach tumor cells throughout the brain. The most commonly used drug for aggressive brain tumors like glioblastoma is temozolomide, taken as a pill in cycles (typically five consecutive days every 28 days). Across clinical trials involving over 700 patients with recurrent glioblastoma, about 14% experienced measurable tumor shrinkage on imaging. That number sounds low, but a broader measure of clinical benefit, which includes tumors that stopped growing or stabilized, reached roughly 50% of patients.
A dosing schedule called metronomic treatment, where lower doses are given more frequently, showed a higher clinical benefit rate of about 61% compared to 46% with standard scheduling. Chemotherapy is rarely used alone for brain tumors. It’s most effective when combined with surgery and radiation.
Targeted Therapy and Edema Reduction
Some of the most debilitating symptoms from brain tumors come not from the tumor itself but from swelling around it. A targeted drug that blocks the growth of new blood vessels has become an important tool for glioblastoma patients. It works by cutting off the signals tumors use to build their own blood supply, which slows growth and dramatically reduces the fluid buildup around the tumor. In studies, patients experienced a median 72% reduction in combined tumor volume and surrounding swelling. This can produce rapid improvement in symptoms like headaches, nausea, and neurological problems.
Corticosteroids like dexamethasone also reduce brain swelling, though they don’t shrink the tumor itself. They work quickly and are commonly given before or after surgery to lower pressure inside the skull, reduce complications, and shorten hospital stays. Many patients take them during radiation as well to manage swelling that treatment can temporarily worsen.
Laser Thermal Therapy for Hard-to-Reach Tumors
For tumors located deep in the brain or in areas too risky for traditional surgery, laser interstitial thermal therapy (LITT) offers a minimally invasive alternative. A thin laser fiber is guided through a small hole in the skull using real-time MRI, then heats and destroys tumor tissue from the inside.
Results vary by tumor type, but the data is encouraging. Low-grade gliomas treated with LITT showed an average size reduction of about 50% within 90 days. High-grade gliomas saw similar 50% reductions in the same timeframe. Grade I meningiomas responded well too, with a 52% size reduction at three months. For tumors that recur after prior radiation, complete laser ablation achieved local control rates of 85 to 100%, while incomplete ablation dropped that rate significantly. The procedure typically requires only one or two nights in the hospital.
Why Tumor Type Changes Everything
The single biggest factor in how a brain tumor responds to treatment is what kind of tumor it is. Meningiomas grow on the brain’s outer coverings, have clear borders, and are usually benign. Most can be cured with surgery alone. Gliomas, on the other hand, grow within the brain tissue itself and send microscopic tendrils into surrounding areas, making complete removal much harder. High-grade gliomas are more aggressive and infiltrate more deeply than low-grade ones.
This infiltration is why gliomas typically require a combination of treatments. Surgery removes the visible mass, radiation targets residual cells, and chemotherapy addresses microscopic disease that has spread beyond the tumor’s borders. Even with all three, high-grade gliomas like glioblastoma frequently recur, which is why ongoing monitoring with regular MRIs is essential. Low-grade gliomas grow more slowly and often respond well to radiation, but they too can eventually regrow at roughly the same rate they were growing before treatment.
How Shrinkage Is Measured
Doctors assess tumor response using standardized criteria that measure the tumor in two perpendicular directions on MRI scans. A tumor needs to be at least 10 millimeters across in both directions to be considered measurable. If multiple tumors are present, the two largest are selected as targets, and their combined measurements are tracked over time. This system ensures that when your doctor says a tumor has “responded” to treatment, it means something specific and reproducible, not just a subjective impression from looking at a scan.
A complete response means no visible tumor remains. A partial response means measurable shrinkage. Stable disease means the tumor hasn’t grown. Progressive disease means it has. These categories guide every subsequent treatment decision, from whether to continue the current approach to whether it’s time to try something different.